查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1967781

高活性原料药（ API）契约製造市场－全球产业规模、份额、趋势、机会和预测：按製剂、最终用途、地区和竞争格局划分，2021-2031年

High Potency API Contract Manufacturing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Formulation, By End Use, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球高活性原料药（HPAPI）契约製造市场预计将从 2025 年的 85.2 亿美元大幅成长至 2031 年的 142.2 亿美元，复合年增长率为 8.91%。

该领域专注于低剂量下即可产生生物效应的药理活性物质的合约生产。由于癌症发病率上升以及製药业向标靶癌症疗法的转型，对这种能力的需求日益增长。处理这些复杂的製剂需要先进的生物安全设施和专业技术，而许多药物研发公司缺乏这些资源，因此越来越依赖具备资格的合约研发生产机构（CDMO）来弥补这一营运缺口。

市场概览
预测期 2027-2031
市场规模：2025年 85.2亿美元
市场规模：2031年 142.2亿美元
复合年增长率：2026-2031年 8.91%
成长最快的细分市场 肿瘤学
最大的市场 北美洲

根据欧洲製药工业协会联合会（EFPIA）的数据，预计到2024年，欧洲製药业在研发领域的投资将达到550亿欧元。如此庞大的药物开发平臺投入凸显了市场对能够安全处理高活性化合物的专业生产合作伙伴日益增长的需求。然而，该产业的成长受到许多障碍的限制，尤其是实施先进的隔离技术和维持严格的监管合规标准以有效防止交叉污染所需的巨额资金。

市场驱动因素

全球癌症和慢性疾病负担日益加重，是推动高活性原料药（API）契约製造行业成长的主要动力。随着癌症发生率的上升，製药研发人员越来越关注低剂量即可发挥疗效的高活性分子。由于处理细胞毒性物质本身存在风险和复杂性，这种转变通常需要采取专门的防护措施，而这些物质的生产也越来越多地外包。根据美国癌症协会于2024年1月发布的《2024年癌症事实与数据》，预计仅在美国就将新增2,001,140例癌症病例。这项统计数据促使生产商与具备完善的安全通讯协定和工业卫生标准的合约组织合作，以扩大这些关键治疗方法的生产规模。

同时，抗体药物复合体（ADC）需求的激增正在重塑製药业的模式。 ADC透过复杂的结合过程，将抗体的特异性与小分子药物的效力结合。自行开发生物製药和化学製剂的生产能力成本高昂，促使生物製药公司转向专业的合约组织，以获得必要的基础设施，同时避免固定成本的负担。三星生物製剂在2024年1月发布的新闻稿印证了这一趋势，新闻稿确认该公司正在其BioCampus II园区内建造一座独立的ADC生产设施，以满足客户需求。此举与整个产业的扩张趋势相符，美国FDA在前一年核准的55种新药就证明了这一点。

市场挑战

高活性原料药（HPAPI）契约製造产业的扩张受到阻碍，主要原因是实施先进的隔离技术和遵守严格的监管标准需要大量的资本投入。生产高活性化合物需要专门的基础设施，例如负压空调系统和坚固的隔离器，以确保工人安全并消除交叉污染的风险。这些设施需要大量的前期投资，并且由于需要维持符合职业暴露限值，营运成本也会增加。这种经济现实有效地阻止了小规模合约研发生产机构（CDMO）进入市场，从而限制了可用供应商的总数。

这种资本密集结构造成了供给能力瓶颈，儘管对高活性化合物的需求不断增长，却阻碍了市场成长。由于能够承担必要设备升级的製造商数量有限，该行业极易受到供不应求和营运柔软性下降的影响。美国化学製造商协会 (SOCMA) 2024 年的数据凸显了这项投资的紧迫性，数据显示，95% 的契约製造製造商和委託製造製造商都制定了资本投资计划以支持新技术和新产品，这凸显了严重的财务负担，并减缓了新产能的部署。

市场趋势

在活性原料药（HPAPI）的契约製造领域，一场向一体化「一站式服务」模式的根本性转变正在进行中。此模式要求合约研发受託製造厂商（CDMO）整合价值链，提供从研发到生产的端到端服务。透过集中处理从分子合成到最终製剂填充和包装的整个流程，可以降低不同供应商之间高活性化合物转移带来的物流风险。这项策略在抗体药物复合体（ADC）复杂的供应链中尤其重要。 2024年9月，Piramal Pharma Solutions宣布投资8,000万美元扩建位于肯塔基州列剋星敦的工厂，凸显了整合趋势。该公司旨在加强其一体化无菌注射剂生产能力，并扩展其全面的「ADCelerate」计画。

同时，市场正从传统的肿瘤治疗领域拓展，高活性原料药（HPAPI）的应用范围正扩展到多种非肿瘤治疗领域。为了满足代谢性疾病（如肥胖症和糖尿病）以及自体免疫疾病对高活性药物日益增长的需求，製造商正在开发基础设施以处理包括胜肽在内的各种药物。为了顺应这一趋势，合约研发生产机构（CDMO）CordenPharma承诺在三年内投资9亿欧元，以加速其在欧洲和美国的GLP-1肽生产。 Labiotech.eu于2024年8月报导了这一消息，这表明CordenPharma坚定致力于支持这些不断扩展的治疗领域。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球高蛋白原料药（HPAPI）契约製造市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 剂型类型（注射剂、口服固态剂型、乳液剂型、其他）
    • 最终用途分类（肿瘤科、抗糖尿病药物、自体免疫疾病、其他）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美高活性原料药（HPAPI）契约製造市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲高活性原料药（HPAPI）契约製造市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区高活性原料药（HPAPI）契约製造市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲高活性原料药（HPAPI）契约製造市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美高活性原料药（HPAPI）契约製造市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球高活性原料药（HPAPI）契约製造市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Catalent, Inc.
  • Lonza Group
  • Piramal Pharma Solutions
  • Pfizer CentreOne
  • Gentec Pharmaceutical Group
  • AbbVie Contract Manufacturing
  • Corden Pharma International
  • Curia Global, Inc.
  • SigmaAldrich Co., LLC
  • Polpharma Group

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 18843

The Global High Potency API (HPAPI) Contract Manufacturing Market is projected to expand significantly, rising from USD 8.52 billion in 2025 to USD 14.22 billion by 2031, reflecting a CAGR of 8.91%. This sector focuses on the outsourced production of pharmacologically active substances that induce biological effects at minute dosages, a capability increasingly sought after due to the rising incidence of cancer and the pharmaceutical industry's shift toward targeted oncology therapies. Since handling these complex modalities requires specialized high-containment infrastructure and expertise that many innovator firms lack internally, there is a growing necessity to rely on competent contract development and manufacturing organizations to bridge this operational gap.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 8.52 Billion
Market Size 2031USD 14.22 Billion
CAGR 2026-20318.91%
Fastest Growing SegmentOncology
Largest MarketNorth America

Data from the European Federation of Pharmaceutical Industries and Associations indicates that in 2024, the pharmaceutical industry allocated an estimated €55,000 million to research and development within Europe. This massive investment in the drug development pipeline highlights the escalating need for specialized manufacturing partners capable of safely managing potent compounds. However, the sector's growth is tempered by substantial barriers, specifically the immense capital required to install advanced containment technologies and maintain rigorous regulatory compliance standards to effectively prevent cross-contamination.

Market Driver

The escalating global burden of oncology and chronic diseases serves as the primary engine for growth in the High Potency API contract manufacturing industry. As cancer rates climb, pharmaceutical developers are increasingly focusing on highly potent molecules that achieve greater efficacy at lower doses, a shift that demands specialized containment measures often outsourced due to the inherent risks and complexities of handling cytotoxic materials. According to the American Cancer Society's "Cancer Facts & Figures 2024," released in January 2024, it was estimated that 2,001,140 new cancer cases would be diagnosed in the United States alone, a statistic that compels manufacturers to partner with contract organizations possessing the established safety protocols and industrial hygiene standards necessary for scaling these critical therapies.

Simultaneously, the manufacturing landscape is being redefined by the surging demand for Antibody-Drug Conjugates (ADCs), which merge antibody specificity with small-molecule potency through complex conjugation processes. Because developing internal capabilities for both biologic and chemical manufacturing is prohibitively expensive, biopharmaceutical companies are turning to specialized contract organizations to access required infrastructure without the burden of fixed costs. This trend is exemplified by Samsung Biologics, which confirmed in a January 2024 press release that it was constructing a standalone ADC facility at its Bio Campus II to support client needs, a move that parallels the industry's broader momentum as evidenced by the U.S. FDA's approval of 55 novel drugs in the preceding year.

Market Challenge

The expansion of the HPAPI contract manufacturing sector is significantly hindered by the high capital expenditures required to install advanced containment technologies and adhere to strict regulatory standards. Producing potent compounds demands specialized infrastructure, such as negative-pressure HVAC systems and rigid isolators, to guarantee operator safety and eliminate the risk of cross-contamination. These facilities necessitate heavy upfront investment and result in elevated operational costs to maintain compliance with occupational exposure limits, a financial reality that effectively bars smaller contract development and manufacturing organizations from entering the market and restricts the overall number of capable suppliers.

This capital-intensive dynamic creates capacity bottlenecks that stifle market growth despite increasing demand for potent compounds. With only a limited number of manufacturers able to afford the requisite upgrades, the industry is vulnerable to supply shortages and diminished operational flexibility. The urgency of these investments is highlighted by 2024 data from the Society of Chemical Manufacturers & Affiliates, which noted that 95% of contract and toll manufacturers intended to undertake capital expenditure projects to support new technologies and products, underscoring the severe financial strain that slows the deployment of new manufacturing capacity.

Market Trends

The HPAPI contract manufacturing sector is undergoing a fundamental shift toward integrated "one-stop-shop" service models, where CDMOs consolidate their value chains to provide end-to-end development and manufacturing. By unifying processes ranging from molecule synthesis to final drug product fill-finish, companies can mitigate the logistical risks involved in transferring potent compounds between different vendors, a strategy particularly crucial for the complex supply chains of antibody-drug conjugates (ADCs). This trend toward consolidation was highlighted in September 2024 by Piramal Pharma Solutions, which announced an $80 million investment to expand its Lexington, Kentucky facility, aiming to enhance its integrated sterile injectable capabilities and bolster its comprehensive "ADCelerate" program.

Concurrently, the market is broadening its scope beyond traditional oncology applications as HPAPI utilization diversifies into non-oncology therapeutic areas. Manufacturers are increasingly adapting their production lines to meet the booming demand for high-potency treatments for metabolic disorders, such as obesity and diabetes, as well as autoimmune diseases, necessitating infrastructure capable of handling diverse modalities like peptides. Reflecting this pivot, the CDMO CordenPharma pledged €900 million over three years to accelerate GLP-1 peptide production in Europe and the United States, as reported by Labiotech.eu in August 2024, signaling a major commitment to supporting these expanding therapeutic categories.

Key Market Players

  • Catalent, Inc.
  • Lonza Group
  • Piramal Pharma Solutions
  • Pfizer CentreOne
  • Gentec Pharmaceutical Group
  • AbbVie Contract Manufacturing
  • Corden Pharma International
  • Curia Global, Inc.
  • SigmaAldrich Co., LLC
  • Polpharma Group

Report Scope

In this report, the Global High Potency API (HPAPI) Contract Manufacturing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

High Potency API (HPAPI) Contract Manufacturing Market, By Formulation

  • Injectables
  • Oral Solids
  • Lotions
  • Others

High Potency API (HPAPI) Contract Manufacturing Market, By End Use

  • Oncology
  • Antidiabetics
  • Autoimmune
  • Others

High Potency API (HPAPI) Contract Manufacturing Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global High Potency API (HPAPI) Contract Manufacturing Market.

Available Customizations:

Global High Potency API (HPAPI) Contract Manufacturing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global High Potency API (HPAPI) Contract Manufacturing Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Formulation (Injectables, Oral Solids, Lotions, Others)
    • 5.2.2. By End Use (Oncology, Antidiabetics, Autoimmune, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America High Potency API (HPAPI) Contract Manufacturing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Formulation
    • 6.2.2. By End Use
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States High Potency API (HPAPI) Contract Manufacturing Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Formulation
        • 6.3.1.2.2. By End Use
    • 6.3.2. Canada High Potency API (HPAPI) Contract Manufacturing Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Formulation
        • 6.3.2.2.2. By End Use
    • 6.3.3. Mexico High Potency API (HPAPI) Contract Manufacturing Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Formulation
        • 6.3.3.2.2. By End Use

7. Europe High Potency API (HPAPI) Contract Manufacturing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Formulation
    • 7.2.2. By End Use
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany High Potency API (HPAPI) Contract Manufacturing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Formulation
        • 7.3.1.2.2. By End Use
    • 7.3.2. France High Potency API (HPAPI) Contract Manufacturing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Formulation
        • 7.3.2.2.2. By End Use
    • 7.3.3. United Kingdom High Potency API (HPAPI) Contract Manufacturing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Formulation
        • 7.3.3.2.2. By End Use
    • 7.3.4. Italy High Potency API (HPAPI) Contract Manufacturing Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Formulation
        • 7.3.4.2.2. By End Use
    • 7.3.5. Spain High Potency API (HPAPI) Contract Manufacturing Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Formulation
        • 7.3.5.2.2. By End Use

8. Asia Pacific High Potency API (HPAPI) Contract Manufacturing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Formulation
    • 8.2.2. By End Use
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China High Potency API (HPAPI) Contract Manufacturing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Formulation
        • 8.3.1.2.2. By End Use
    • 8.3.2. India High Potency API (HPAPI) Contract Manufacturing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Formulation
        • 8.3.2.2.2. By End Use
    • 8.3.3. Japan High Potency API (HPAPI) Contract Manufacturing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Formulation
        • 8.3.3.2.2. By End Use
    • 8.3.4. South Korea High Potency API (HPAPI) Contract Manufacturing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Formulation
        • 8.3.4.2.2. By End Use
    • 8.3.5. Australia High Potency API (HPAPI) Contract Manufacturing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Formulation
        • 8.3.5.2.2. By End Use

9. Middle East & Africa High Potency API (HPAPI) Contract Manufacturing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Formulation
    • 9.2.2. By End Use
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia High Potency API (HPAPI) Contract Manufacturing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Formulation
        • 9.3.1.2.2. By End Use
    • 9.3.2. UAE High Potency API (HPAPI) Contract Manufacturing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Formulation
        • 9.3.2.2.2. By End Use
    • 9.3.3. South Africa High Potency API (HPAPI) Contract Manufacturing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Formulation
        • 9.3.3.2.2. By End Use

10. South America High Potency API (HPAPI) Contract Manufacturing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Formulation
    • 10.2.2. By End Use
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil High Potency API (HPAPI) Contract Manufacturing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Formulation
        • 10.3.1.2.2. By End Use
    • 10.3.2. Colombia High Potency API (HPAPI) Contract Manufacturing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Formulation
        • 10.3.2.2.2. By End Use
    • 10.3.3. Argentina High Potency API (HPAPI) Contract Manufacturing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Formulation
        • 10.3.3.2.2. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global High Potency API (HPAPI) Contract Manufacturing Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Catalent, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Lonza Group
  • 15.3. Piramal Pharma Solutions
  • 15.4. Pfizer CentreOne
  • 15.5. Gentec Pharmaceutical Group
  • 15.6. AbbVie Contract Manufacturing
  • 15.7. Corden Pharma International
  • 15.8. Curia Global, Inc.
  • 15.9. SigmaAldrich Co., LLC
  • 15.10. Polpharma Group

16. Strategic Recommendations

17. About Us & Disclaimer